u/Final-Cap2763

I’m building something and want to learn from folks who take their investing seriously, somewhere between casual retail and full-time professional. Think self-directed investors managing meaningful personal capital, running real DCFs, reading 10-Ks and 8-Ks cover to cover, maintaining watchlists with actual theses behind them.

I’d love to hear about your workflow:
- How do you source and filter ideas?
- Where does your research live (notes, spreadsheets, etc.)?
- What’s the most painful or time-consuming part of your process?
- What tools have you tried and ditched, and why?

Not selling anything, not pitching a product. Just trying to understand how you guys actually work.

Hims & Hers reported last night and the consensus take I'm seeing is that it was a decent quarter — revenue $608M (+4% YoY), EBITDA in line, FY26 revenue ceiling raised to $3.0B. Stock is being treated as a "growth story intact" name.

I spent some time on the segment disclosures and I think the bull case is materially weaker than the headlines suggest. Sharing the work in case anyone else is looking at this name.

The core issue: US revenue declined 8.4% YoY

The geographic split:

• United States: $530M, down 8.4% YoY
• Rest of World: $78M, +969% YoY (off a near-zero base - this is the Zava/LiveWell acquisition that didn't exist a year ago)
• Consolidated: $608M, +4% YoY

The only reason consolidated growth was positive is that they bolted on an international footprint that didn't exist in the comp period. The core US business - which is ~87% of revenue and the entire historical thesis - is in contraction.

ARPU also declined to $80 from $85 (-6% YoY). So it's not subscriber growth carrying the line, and it's not monetization. It's geography.

The guide change tells you what management sees

• FY26 revenue range: $2.7-2.9B → $2.8–3.0B (ceiling raised $100M)
• FY26 EBITDA midpoint: $337.5M → $312.5M (cut $25M)
• FY26 EBITDA margin: 11-13% → 10–12% (cut 100bps)

Higher revenue, lower profit dollars, lower margin. That's a mix-shift admission, not an acceleration. They're guiding to more lower-margin business (branded GLP-1, international, new categories like testosterone/menopause which Yemi explicitly called lower-margin on the call).

The Q2 guide is the part I can't make work

Q2 guide: $680-700M, implying +25–28% YoY.

The Q1 print was +4%. To get from +4% to +25% in 90 days, with US revenue declining 8.4%, you need either:

1. The US business to swing from -8% to meaningfully positive in one quarter, or
2. ROW to roughly double sequentially

The bull case rests on the branded GLP-1 pivot - Wegovy via Novo Nordisk, ZepBound via Lilly Direct. Management volunteered they're adding 100k+ new branded weight-loss subscribers per month and shipped 125k+ Wegovy orders in six weeks. Fine. But that's volume, not revenue. And critically, they stopped disclosing total weight-loss subscriber growth this quarter (last quarter it was +70%) and switched to "branded subscribers" only. When a company changes its disclosure framework right as the underlying number is supposed to be inflecting, that's usually a tell.

Tone observation

Reaffirmed 2030 targets ($6.5B revenue, $1.3B EBITDA) while cutting FY26 EBITDA. From the lower FY26 base, hitting 2030 implies a ~33% EBITDA CAGR they have no track record of delivering. Reaffirming the destination while quietly moving the intermediate milestones is something you see at this stage of a lot of growth stories that don't end well.

What I'm watching

• Q2 revenue print vs $680M low end - if it misses, the whole acceleration narrative breaks
• US revenue YoY in Q2 - the cleanest signal, much harder to obscure than the consolidated number
• Q2 EBITDA margin vs 5-8% guide - a print at the low end basically confirms FY26 EBITDA gets cut again
• Peptide FDA classification expected end of July - one of the only concrete near-term catalysts management flagged
• Whether they disclose any actual revenue or contribution figure for branded weight loss, vs just subscriber adds

What I might be wrong about

The bull pushback is real: branded GLP-1 demand is genuinely accelerating, the Eucalyptus acquisition (closing H2 2026, $240M at close) does extend the international platform, and the peptide opportunity is uncapped. If the Q2 print actually comes in at $700M and US returns to growth, this thesis falls apart and I look silly. Open to that being the outcome.

No position either way - just struck me how different the segment data reads from the headline. Curious what others are seeing, especially anyone long the name and willing to push back on the US-decline read.

I spent a lot of time reading Apple's Q2 FY2026 earnings call (reported April 30, 2026) and most coverage I saw focused on the revenue beat (+17% YoY) and Tim Cook's announcement that he's transitioning to executive chairman with John Ternus taking over as CEO on September 1.

The succession is a big deal - Apple's first formal CEO transition since Cook took over from Jobs in 2011. But after going through the prepared remarks and Q&A carefully, I think there are three things from this print that got under-covered, and one of them is structurally more important than the succession itself.

1. Apple quietly retired its net-cash-neutral target - a framework it had used since 2018.

This was buried in CFO Kevan Parekh's prepared remarks. His exact words: "we are no longer providing net cash neutral as a formal target, and we will independently evaluate cash and debt."

For context: since 2018, Apple has been on a stated path to reach a "net cash neutral" balance sheet - meaning total cash roughly equal to total debt. The framework drove the massive buyback program ($850B+ returned to shareholders cumulatively) and constrained how Apple could use its balance sheet.

Retiring it does two things:

• Opens the door to debt-funded buybacks at scale (Apple can now carry net debt without violating its own framework)
• Frees up cash for sustained AI infrastructure capex without requiring offsetting returns

Paired with a $100B additional buyback authorization announced the same day, this is the most consequential capital structure shift Apple has made in over a decade. The succession is news for one quarter. This is news for the next 10 years of how Apple uses its $200B+ balance sheet.

Almost no mainstream coverage I saw mentioned the framework retirement, much less weighted it correctly.

2. The Q3 gross margin guide of 47.5-48.5% is the first forward-margin step-down in four quarters.

Apple just reported 49.3% gross margin in Q2 - above the top of their guide. The new Q3 guide is 47.5-48.5%, which is 80-180 basis points below what they just delivered.

In Q&A, Cook explicitly flagged the reason: memory costs. His framing: "beyond the June quarter, we believe memory costs will drive an increasing impact on our business."

Memory pricing has been ramping for two quarters and Apple has been absorbing it via Services mix leverage. The guide step-down suggests the leverage is starting to run out as a sufficient offset. Worth tracking whether Apple's margin walks down further in the September quarter (Q4 FY2026), which would confirm a multi-quarter memory headwind cycle.

3. The Services growth guidance construct quietly changed.

This one's subtle but worth flagging. Apple previously guided Services growth as a specific percentage range ("similar to fiscal year 2025 rate" implying ~14%). This quarter the guide changed to "similar to March quarter after removing FX tailwinds."

Translation: the headline Services rate (16.3% in Q2) included a meaningful FX boost. The "similar after removing FX" guide implies organic Services growth is moderating from the reported rate, but the new construct makes it harder to calculate the underlying trajectory.

This is the kind of disclosure-quality regression that compounds: each quarter the guide gets a little less precise, and reader has to do more work to figure out what's actually being said. Worth watching whether the next quarter continues this pattern or returns to a quantified range.

Why this matters beyond Apple:

The general pattern is that quarterly earnings carry 3-5 substantive forward-relevant signals per call, and only 1-2 of them make headlines. Cross-quarter context is what surfaces the others. Looking at Apple's Q2 in isolation makes the succession look like the story; looking at it as the fourth in a sequence (Q3 FY25 → Q4 → Q1 FY26 → Q2 FY26) makes the capital structure retirement obvious as the more durable signal.

For anyone reading earnings calls seriously: the questions to ask aren't just "what did they say?" but "what did they stop saying?" and "what changed in how they're framing it?"

What's everyone else watching for Apple's Q3 (calendar June 2026)? I'm specifically tracking the gross margin guide outcome, whether Greater China sustains above +20% YoY, and any concrete update on personalized Siri delivery (Cook reaffirmed "coming this year" but no specific date for the third consecutive call).

Disclosure: I write Tapebrief, an automated earnings analysis tool I built for my own work. Happy to discuss methodology in comments.